UBS has initiated coverage for the following companies:
Par Pharmaceutical Companies PRX Buy, $35 price target
Alkermes Inc. ALKS Buy, $18 price target
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: InitiationAnalyst RatingsalkermesBiotechnologyHealth Carepar pharmaceuticalPharmaceuticalsUBS
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in